Recruiting soon

Pegasus 2Lung Perfusion PET/CT for Reduced Radiation Injury in Lung SBRT

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Conventional anatomical planning radiotherapy

+ Functional Lung avoidance planning

Radiation
Who is being recruted

Disease+7

+ Lung Diseases

+ Lung Neoplasms

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: January 2026
See protocol details

Summary

Principal SponsorUniversity Hospital, Brest
Study ContactPierre-Yves Le Roux, Professeur
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 15, 2026

Actual date on which the first participant was enrolled.

This study focuses on improving the way radiation treatment is planned for patients with lung tumors. It aims to reduce the risk of lung damage that can occur as a side effect of stereotactic body radiotherapy (SBRT), a common treatment for lung cancer. A new imaging technique, 68Ga-MAA lung perfusion PET/CT, is being tested to create a more personalized treatment plan by identifying which parts of the lung are most functional and should be protected during radiation. The goal is to minimize lung injury, which can affect up to 20% of patients, by targeting the radiation more precisely. Participants in this study will undergo SBRT guided by this new imaging method to compare its effectiveness against the traditional planning method that uses anatomical lung images. The study will assess whether this functional planning approach reduces the occurrence of significant lung toxicity, known as radiation-induced lung injury, within a year after treatment. The effects will be measured by a medical oncologist who does not know which treatment plan each participant received, ensuring unbiased results. This research could lead to safer and more effective lung cancer treatments by protecting lung function while still effectively treating the tumor.

Official TitleFunctional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy
Principal SponsorUniversity Hospital, Brest
Study ContactPierre-Yves Le Roux, Professeur
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

418 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DiseaseLung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SitePathologic ProcessesRespiratory Tract DiseasesRespiratory Tract NeoplasmsPathological Conditions, Signs and SymptomsThoracic Neoplasms

Criteria

Inclusion Criteria: * Patients aged \> 18 years planned to be treated in the radiotherapy department of the participating centers with SBRT for primary or secondary lung tumors will be eligible to participate into the study Exclusion Criteria: * Inability to give informed consent * Patientsunder guardianship or curatorship * Pregnant or breastfeeding women. * Contraindications to the radiolabeled product infused for lung perfusion PET/CT.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
A conventional anatomical planning will be performed.

Group II

Experimental
functional planning will be carried out, respecting the standard constraints especially to the tumor and the anatomical lung volume, but also incorporating "lung functional volume" constraints defined by regional lung function mapping.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 2 locations

Suspended

CHU Brest

Brest, FranceOpen CHU Brest in Google Maps
Suspended

Centre de Lutte Contre le Cancer Leon Bérard Lyon

Lyon, France
Recruiting soon2 Study Centers